Core Insights - Heptares Therapeutics has entered into an evaluation and licensing agreement with Umoja Biopharma to combine their respective platforms for the development of in vivo CAR-T cell products, marking a deepening of their strategic partnership established in September 2024 [1][2] Company Overview - Umoja Biopharma is a clinical-stage biotechnology company focused on developing more accessible and effective in vivo CAR-T cell therapies for oncology and autoimmune diseases [2] - The company's VivoVec gene delivery technology enhances the patient's immune system's ability to combat diseases, supported by an advanced manufacturing facility located in Louisville, Colorado [2] - Umoja Biopharma aims to improve the accessibility and effectiveness of immunotherapies, helping more patients lead better and fuller lives [2]
和铂医药-B(02142.HK)与Umoja Biopharma订立评估与授权协议 共同推进多款体内CAR-T细胞产品研发